Retatrutide 10mg
$149.99
Retatrutide 10mg
Triple GLP-1/GIP/Glucagon receptor agonist
CAS: 2381089-83-2
Retatrutide (GLP-3 R) 10mg — the starter supply. Triple GLP-1/GIP/Glucagon receptor agonist. Ideal for initiating the Clav stack protocol.
For research purposes only. Not intended for human use.
Triple-Agonist: GLP-1R + GIPR + GcgR
Retatrutide activates three receptors simultaneously. GLP-1R drives appetite suppression. GIPR enhances insulin sensitivity and adipocyte lipid metabolism. GcgR activates hepatic beta-oxidation and brown adipose thermogenesis. Phase 2 data: −28.7% body weight at 48 weeks.
Starter Vial
The 10mg vial provides sufficient supply to begin a Retatrutide dose escalation protocol. Starting at 2mg/week, a 10mg vial covers approximately 5 weeks of initiation phase research.
Phase 2 Data
Same compound as all GLP-3 R vials — Phase 2 showed −28.7% at 8mg/week over 48 weeks. The 10mg starter allows research to begin without committing to larger supply.
>98% Purity
HPLC tested lyophilized powder. Same purity specification across all Retatrutide vial sizes.
Specifications
Research FAQ
How long does 10mg of Retatrutide last?
At 2mg/week initiation dose, 10mg covers 5 weeks. At 4mg/week, 2.5 weeks. For a full escalation cycle (2→4→8mg), the 15mg or 30mg vials provide better value.
Is the 10mg the same compound as the 15mg/30mg vials?
Yes — identical Retatrutide compound and purity specification. Only the vial size differs.
Related Products
BPC-157 + TB-500 Blend 20mg
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.
CAS: 137525-51-0
BPC-157 10mg
Buy BPC-157 10mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.
CAS: 137525-51-0
